AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Carl Hansen

Kevin Heyries

Véronique Lecault

AbCellera Biologics Inc.

60 Degrees Pharmaceuticals is engaged in the development and commercialization of medicines and therapies for infectious diseases.

60 Degrees Pharmaceuticals

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Austin Che

Tom Knight

Jason Kelly

Barry Canton

Reshma Shetty

Ginkgo Bioworks Holdings, Inc.

Iktos leverages AI and robotics to transform drug discovery, integrating generative AI with automated synthesis and testing to accelerate the development of new treatments.

Metric
Company Name	AbCellera Biologics Inc.	60	Ginkgo Bioworks Holdings, Inc.	Iktos
Symbol	ABCL		DNA
MSH ID	COM:ABCELLERA	COM:60DEGREESPHARMA	COM:GINKGOBIOWORKS	COM:IKTOS
Market	STOCKS	PRIVATE	STOCKS	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Pharmaceuticals	Biotechnology	Pharmaceuticals
Country	CA	US	US	FR
Stage			Grant	Series A
Employee Count	586		1.22K
Website	abcellera.com	60degreespharma.com	ginkgobioworks.com	iktos.com
LinkedIn			ginkgo-bioworks	iktos
Founders

Metric
Market Cap	823.35M	725.64M
Enterprise Value
Monthly Web Traffic		20.69K	1.21K
Web Traffic Growth		-0.17	-0.40
Valuation
Raised Capital			16.41M

Metric
Revenue	38.02M	251.46M
Revenue (LTM)
Revenue (NTM)
Gross Profit	7.13M	142.64M
EBITDA	-192.16M	-600.68M
Operating Income	-237.21M	-672.23M
Net Income	-146.40M	-892.87M
EPS	-0.51	-0.46
Diluted EPS	-0.51	-0.46
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.30	0.75
Operating Profit Margin	-6.15	-3.34
EBITDA Margin	-5.05	-2.39
Net Profit Margin	-3.85	-3.55
Return on Equity	-0.12	-0.65
Return on Assets	-0.10	-0.54
Return on Capital Employed	-0.17	-0.51

COM:ABCELLERA

AbCellera Biologics Inc.

Last Close

2.72

22/11 21:00

Market Cap

823.35M

Beta: -

Volume Today

2.82K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-11.06	-2.78
P/B Ratio	1.21	1.90
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	35.65	93.70
EV Multiple	-4.01	-1.34

Metric
Days Sales Outstanding	546.74	73.17
Days Payables Outstanding	4.09K	50.57
Days Inventory Outstanding	8.82	0.27
Operating Cycle	747.59	46.33
Cash Conversion Cycle	589.35	-7.39
Asset Turnover	0.05	0.15

Metric
Operating Cash Flow	-43.88M	-295.50M
Free Cash Flow	-121.38M	-336.30M
Cash Flow to Debt	-0.56	-0.63
Operating Cash Flow/Sales	-1.15	-1.14
Free Cash Flow Yield	-0.05	-0.16

Metric
Cash & Equivalents	133.32M	948.86M
Accounts Receivable	-45.93M	50.07M
Inventory	1.11M	46K
Goodwill	47.81M	49.24M
Debt to Capitalization	0.06	0.35
Debt to Assets	0.05	0.20
Current Ratio	8.34	6.78
Quick Ratio	10.96	5.98

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	1.21	0.94
R&D to Revenue	3.08	2.05
SG&A to Revenue	1.15	1.32